{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010311","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.766922+00:00","generated_at":"2026-06-17T07:43:13.809550+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Daré Bioscience enters into ATM equity offering program with Stifel and Cantor","bullets":["Entered into sales agreement with Stifel and Cantor for at-the-market equity offering of common stock.","Commission of 3.0% of gross proceeds payable to sales agents.","Shares sold under existing shelf registration statement filed March 30, 2021.","Company sets parameters including maximum shares, time period, and minimum price.","Sales may be made on Nasdaq or in privately negotiated transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010311","json":"https://secwatch.observer/filing/0001493152-23-010311.json","markdown":"https://secwatch.observer/filing/0001493152-23-010311.md","text":"https://secwatch.observer/filing/0001493152-23-010311.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223010311/0001493152-23-010311-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223010311/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:43:13.809550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b9ec7982ff72ac482372f57e7ea321965797217","claim":"Dare Bioscience, Inc. entered into Sales Agreement with Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. (effective 2023-03-31).","evidence_excerpt":"On March 31, 2023, Daré Bioscience, Inc. (“we,” “us,” “our”), entered into a sales agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel Nicolaus”) and Cantor Fitzgerald & Co. (“Cantor”) to sell shares of our common stock from time to time through an “at-the-market” equity offering program under which Stifel Nicolaus and Cantor will act as our sales agents (each individually a “Sales Agent” and together, the “Sales Agents”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223010311/0001493152-23-010311-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co."},{"label":"Effective","value":"2023-03-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}